An Overview of Suzetrigine: Exploring its Mechanism, Safety Profile and Role as a Novel Non-Opioid Analgesic - A Mini Review

Abstract

Background: Acute pain is one of the most common reasons for people to visit doctors worldwide. Opioids are still useful analgesics, but their use is limited by side effects such as respiratory depression, tolerance, dependence, and potential for abuse. Therefore, the development of non-opioid analgesics with novel mechanisms of action has become a major research goal.

Objective: The present paper is a review of the known data on suzetrigine as a novel non-opioid analgesic, covering its pharmacology, mechanism of action, pharmacokinetics, efficacy and safety in clinical use, current regulatory status and possible future indications.

Methods: A comprehensive literature study was performed using peer-reviewed articles, clinical trial reports, regulatory documents, and published reviews available in large scientific databases. A comprehensive analysis and synthesis of relevant research on NaV1.8 inhibition, preclinical studies, clinical trials, and new developments in the development of suzetrigine was performed.

Results: Suzetrigine selectively blocks NaV1.8 channels, which are expressed on peripheral sensory neurons, and suppresses pain signals while not significantly influencing the central nervous system. Clinical research has demonstrated that patients with moderate-to-severe acute postoperative pain may benefit from effective analgesia with a favorable safety and tolerability profile. Suzetrigine has not shown any evidence of respiratory depression or clinically significant addiction potential, unlike opioid analgesics. The pharmacokinetic profile of pregabalin is compatible with convenient oral administration and its potential utility in inflammatory and chronic neuropathic pain conditions is under investigation.

Conclusion: A major breakthrough in non-opioid pain treatments is the highly selective inhibition of NaV1.8 by Suzetrigine. Its efficacy, good safety and low risk of opioid related adverse effects make it a potential alternative to acute pain management. Longer-term clinical studies are needed to ascertain its relevance in chronic pain disorders and in more general clinical practice.